Modular Medical (MODD)
Early-commercial maker of reusable-component tubeless insulin patch pumps.
Something off on this page? Send us feedback.
Begins commercializing a reusable-component, tubeless insulin patch pump for U.S. adults who have not adopted existing pumps. The planned model pairs pump sales with recurring disposable components and depends on reimbursement, training, distributor reach, and regulated manufacturing.
Designs and is beginning to commercialize Pivot, a prescription-only tubeless insulin patch pump for U.S. adults who require insulin. The system delivers basal and user-initiated bolus insulin through a removable patch, pairing a reusable pumping component with disposable three-day elements. It is aimed at people who still use multiple daily injections and have not adopted conventional pumps.
Plans to sell the reusable pump with recurring cartridges and infusion components, using distributors for patients managed in primary care and a small direct team for diabetes-educator practices. Product and process development are internal, while infusion sets and manufacturing support come from third parties, including Phillips-Medisize.
Launch execution depends on FDA quality and post-market obligations, reimbursement, prescription fulfillment, training, manufacturing reliability, and acceptance from patients, clinicians, distributors, and payors. Pivot is the only intended commercial product after MODD1 was superseded before commercialization.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.9M · Total debt $278.0K · Total assets $12.3M · Shareholders' equity $10.8M
- Revenue
- $0
- Operating income
- −$6.5M
- Net income
- −$6.5M
No dividends on record.
| Institutions | 82.99% | 1.75M shares | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Insiders | 1.01% | 21.3K shares | |
| 4 holders · as of Jul 2, 2026 | |||
| Strategic holders | 6.68% | 140.9K shares | |
| 1 holder · as of Mar 24, 2025 | |||
| Other | 9.32% | 196.7K shares | |
| remainder | |||
2.11M company shares as of Sep 11, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (8.15M in the company's Sep 22, 2026 report, 2.11M elsewhere); stakes use the report.
A stock split fell inside the quarter, so quarter-on-quarter changes are not shown.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Awm Investment Company, Inc.Institution | 20.91% | 441,095 | as of Jun 30, 2026 |
Solas Capital Management, LLCInstitution | 20.77% | 438,095 | as of Jun 30, 2026 |
Bleichroeder LPInstitution | 15.97% | 336,986 | as of Jun 30, 2026 |
Manchester Management Co LLCStrategicdirector, 10 percent owner, officer, other: Chief Executive Officer | 6.68% | 140,919 | filed Mar 24, 2025 |
683 Capital Management, LLCInstitution | 6.16% | 130,000 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Insulet
Closest head-to-head in tubeless insulin patch pumps.
- Tandem Diabetes Care
Established pump platforms compete for U.S. insulin-pump starts.
- Medtronic
Large diabetes-device incumbent with automated pump therapy.
- Beta Bionics
Automation-led alternative for insulin users leaving injections.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Modular Medical | $2.31 | +2.21% | $4.8M | — | — | — | — |
| Insulet | $139.98 | −0.39% | $9.73B | 26.3 | 20.3 | 3.2 | +23.5% |
| Tandem Diabetes Care | $17.13 | −2.78% | $1.21B | — | — | 1.2 | +5.8% |
| Medtronic | $91.63 | −0.14% | $117.44B | 22.6 | 15.3 | 3.1 | +13.7% |
| Beta Bionics | $23.49 | +6.59% | $991.6M | — | — | 8.3 | +37.8% |
| Median | 24.4 | 17.8 | 3.2 | +18.6% |